Voydeya is an oral complement factor D inhibitor added to standard therapy in adults with paroxysmal nocturnal hemoglobinuria. It helps reduce ongoing hemolysis outside blood vessels, improving anemia.
To Get Full Access :
To Get Full Access :
Voydeya is an oral complement factor D inhibitor added to standard therapy in adults with paroxysmal nocturnal hemoglobinuria. It helps reduce ongoing hemolysis outside blood vessels, improving anemia.
The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.
Molecule Name :
Innovator :
Approval Date :
NCE-1 Date :
NCE Date :
Dosage Form :
Strength :
Therapeutic Category :
Revenue ($M) :
2025 :
2026 :
2027 :
2028 :
2029 :
2030 :
2031 :





For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.